<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87195">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01712451</url>
  </required_header>
  <id_info>
    <org_study_id>LIPO-102-CL-11</org_study_id>
    <nct_id>NCT01712451</nct_id>
  </id_info>
  <brief_title>Dose-ranging Study</brief_title>
  <acronym>LIPO-102-CL-11</acronym>
  <official_title>Dose-ranging Study of the Safety and Efficacy of Fluticasone Propionate and Salmeterol Xinafoate in Healthy Patients With Abdominal Contour Defects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lithera, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lithera, Inc</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dose ranging study
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>8 weeks treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>physical exam, vital signs, clinical assessment of injection, clinical laboratory tests, and adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in abdominal circumference</measure>
    <time_frame>Baseline to 9 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>abdominal circumference</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in global clinician scale score</measure>
    <time_frame>Baseline to 9 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in global patient scale score</measure>
    <time_frame>Baseline to 9 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Photonumeric scale score</measure>
    <time_frame>Baseline to 9 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Reported Outcome Score</measure>
    <time_frame>Baseline to 9 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Abdominal Contour Defects</condition>
  <arm_group>
    <arm_group_label>LIPO-102, Low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LIPO-102, Mid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LIPO-102, High</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LIPO-102; Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>salmeterol xinafoate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>salmeterol xinafoate, fluticasone propionate</intervention_name>
    <description>LIPO-102</description>
    <arm_group_label>LIPO-102, Low</arm_group_label>
    <arm_group_label>LIPO-102, Mid</arm_group_label>
    <arm_group_label>LIPO-102, High</arm_group_label>
    <other_name>LIPO-102</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>LIPO-102; Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>salmeterol xinafoate</intervention_name>
    <description>Salmeterol</description>
    <arm_group_label>salmeterol xinafoate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 - 45 years of age inclusive

          -  abdominal contour defect

          -  BMI &lt;25 kg/msq

          -  Stable diet and exercise and body weight

        Exclusion Criteria:

          -  Prior treatment of abdominal contour defects (liposuction, abdominoplasty, etc)

          -  Known hypersensitivity to study drugs
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Murray Maytom</last_name>
    <role>Study Director</role>
    <affiliation>Lithera, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 23, 2012</lastchanged_date>
  <firstreceived_date>October 16, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adiposity</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Salmeterol</mesh_term>
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Fluticasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
